Patients with HHT received pomalidomide or placebo for 24 weeks. Pomalidomide reduced epistaxis frequency and severity.
The New England Journal of Medicine: Search Results in Hematology/Oncology
Pomalidomide for Epistaxis in Hereditary Hemorrhagic Telangiectasia
